Entrepreneur boosts Cambridge neural technology startup
BIOS, a Cambridge startup company that uses AI to code the signals from the brain to the body to treat chronic health conditions, has appointed personalised medicines specialist Professor Joanne Hackett to chair the board.
As the company enters its clinical development phase, Professor Hackett’s background as an entrepreneur, scientist, and strategist, and her experience in scaling and commercialising biotech innovations will be vital, the company says.
BIOS is a full-stack neural interface platform startup and the latest coup could not be more timely.
Professor Hackett brings over 20 years of experience and leadership roles in the biotech and life sciences sector. An accomplished entrepreneur, scientist, and strategist, she has deep expertise in scaling and commercialising biotech innovations.
She says: “BIOS is an agile, fast paced and ambitious entrepreneurial biotech. These are crucial characteristics of successful early stage companies. The interface between technology and the human body is one of the most important fields helping us move beyond incremental changes to our approach to health.
“The platform that BIOS is developing could lead to a much bigger step change and is something I could not wait to be a part of.
“I have been fortunate enough to develop a global portfolio of companies I am involved with, each of which presents a unique challenge and a tremendous opportunity to learn. I look forward to helping BIOS realise its potential, and am excited by the opportunity to learn more about such an exciting field.”
Co-founded by Cambridge University graduates Emil Hewage, a computational neuroscientist, and Oliver Armitage, a biomechanical engineer, BIOS boasts a wide range of experts from neuroscience and artificial intelligence, software engineering and medicine.
Combined, the team brings 300+ peer-reviewed publications, 6,000+ clinical procedures, and 10+ first-of-kind medical devices to the party. The business is backed by UK and North American investors.
Emil Hewage, CEO and co-founder, said: “Professor Hackett’s background as a clinical researcher and senior executive at both Fortune 500 companies and startups have given her a unique ability to identify innovations and bring them to maturity.
“As one of the key global figures in personalised medicine, she immediately enhances the presence of BIOS in the sector. She is an experienced and highly skilled operator and we’re thrilled to have her support and guidance as we continue our rapid growth.”